1-Lim SS, Vos T, Flaxman AD, et al . A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224–2260
2-Stosic, M., Vukovic, D., Babic, D. et al. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study. BMC Public Health 18, 1114 (2018). https://doi.org/10.1186/s12889-018-6021-5.
3-World Health Organization. Global tuberculosis report 2013. Geneva, Switzerland, 2013
4-East African/British Medical Research Council. Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 1977; 116: 3–8.
5-Stop TB Partnership Civil society-led TB/COVID-19 Working Group. The impact of COVID-19 on the TB epidemic: a community perspective. Geneva, Switzerland: Stop TB Partnership, 2020. http://www.stoptb.org/assets/documents/resources/publications/acsm/Civil%20Society%20Report%20on%20TB%20and%20COVID.pdf?fbclid=IwAR3SOY4kyBs5a_35HIeUhcvwRIWspePA4vVHESqcQxio7G4irivJ90cSU8k Accessed November 2020
6-WHO. Global Tuberculosis Report 2019.
7-A profile of a retrospective cohort of 22 patients with COVID-19 and active/treated tuberculosis. Gupta N, Ish P, Gupta A, Malhotra N, Caminero JA, Singla R, Kumar R, Yadav SR, Dev N, Agrawal S, Kohli S, Sen MK, Chakrabarti S, Gupta NK Eur Respir J. 2020 Nov; 56(5):.
8-Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, Andréjak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, Luiza De Souza-Galvão M, Dominguez-Castellano A, Dourmane S, Fréchet Jachym M, Froissart A, Giacomet V, Goletti D, Grard S, Gualano G, Izadifar A, Le Du D, Marín Royo M, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Rivière F, Rodrigo T, Silva DR, Sánchez-Montalvá A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E, Tabernero E, Tambyah PA, Tiberi S, Torre A, Visca D, Zabaleta Murguiondo M, Sotgiu G, Migliori GBEur Respir J. 2020 Jul; 56(1):.
9-Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Western Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Clin Infect Dis. 2021 Oct 5; 73(7):e2005-e2015.
10-Demkina AE, et al. medRxiv. 2020. Risk factors for outcomes of COVID-19 patients: an observational study of 795 572 patients in Russia. 2020.11.02.20224253.
11-McQuaid, C F et al. “The impact of COVID-19 on TB: a review of the data.” The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease vol. 25,6 (2021): 436-446. doi:10.5588/ijtld.21.0148
12-Deshpande D, Pasipanodya JG, Srivastava S, Martin KR, Athale S, van Zyl J, Antiabong J, Koeuth T, Lee PS, Dheda K, Gumbo T. Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis. J Infect Dis. 2019 Feb 23;219(6):975-985. doi: 10.1093/infdis/jiy587. PMID: 30597040.
13-Gautam, U. S., Foreman, T. W., Bucsan, A. N., Veatch, A. V., Alvarez, X., Adekambi, T., Golden, N. A., Gentry, K. M., Doyle-Meyers, L. A., Russell-Lodrigue, K. E., Didier, P. J., Blanchard, J. L., Kousoulas, K. G., Lackner, A. A., Kalman, D., Rengarajan, J., Khader, S. A., Kaushal, D., & Mehra, S. (2018). In vivo inhibition of tryptophan catabolism reorganizes the tuberculoma and augments immune-mediated control of Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 115(1), E62–E71. https://doi.org/10.1073/pnas.1711373114
14-Clemens, V., Regen, F., Le Bret, N. et al. Anti-inflammatory effects of minocycline are mediated by retinoid signaling. BMC Neurosci 19, 58 (2018). https://doi.org/10.1186/s12868-018-0460-x
15-Dutta RK, Kathania M, Raje M, Majumdar S. IL-6 inhibits IFN-γ induced autophagy in Mycobacterium tuberculosis H37Rv infected macrophages. Int J Biochem Cell Biol. 2012 Jun;44(6):942-54. doi: 10.1016/j.biocel.2012.02.021. Epub 2012 Mar 7. PMID: 22426116.
16-Review Effects of vitamin a supplementation on immune responses and correlation with clinical outcomes. Villamor E, Fawzi WW Clin Microbiol Rev. 2005 Jul; 18(3):446-64.
17-Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Iwata M, Eshima Y, Kagechika H Int Immunol. 2003 Aug; 15(8):1017-25.
18-Retinoic acid and polyriboinosinic:polyribocytidylic acid stimulate robust anti-tetanus antibody production while differentially regulating type 1/type 2 cytokines and lymphocyte populations. Ma Y, Chen Q, Ross AC J Immunol. 2005 Jun 15; 174(12):7961-9.
19-Yamada, H., Mizuno, S., Ross, A. C., & Sugawara, I. (2007). Retinoic acid therapy attenuates the severity of tuberculosis while altering lymphocyte and macrophage numbers and cytokine expression in rats infected with Mycobacterium tuberculosis. The Journal of nutrition, 137(12), 2696–2700. https://doi.org/10.1093/jn/137.12.2696
20-Abd-Nikfarjam B, Nassiri-Asl M, Hajiaghayi M, Naserpour Farivar T. Role of Chicoric Acid and 13-Cis Retinoic Acid in Mycobacterium tuberculosis Infection Control by Human U937 Macrophage. Arch Immunol Ther Exp (Warsz). 2018 Oct;66(5):399-406. doi: 10.1007/s00005-018-0511-0. Epub 2018 Apr 27. PMID: 29704020.
21-Talat, N., Perry, S., Parsonnet, J., Dawood, G., & Hussain, R. (2010). Vitamin d deficiency and tuberculosis progression. Emerging infectious diseases, 16(5), 853–855. https://doi.org/10.3201/eid1605.091693
22-David A. Jolliffe, Davaasambuu Ganmaa, Christian Wejse, Rubhana Raqib, Md. Ahsanul Haq, Nawal Salahuddin, Peter K. Daley, Anna P. Ralph, Thomas R. Ziegler, Adrian R. Martineau. Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data. European Respiratory Journal, 2019; 1802003 DOI: 10.1183/13993003.02003-2018
23-Esteban L, Eisman J, Gardiner E. Vitamin D receptor promoter and regulation of receptor expression. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2. New York: Elsevier/Academic Press; 2005. pp. 193–217
24-Cheng TY, Goodman GE, Thornquist MD, Barnett MJ, Beresford SA, LaCroix AZ, Zheng Y, Neuhouser ML. Estimated intake of vitamin D and its interaction with vitamin A on lung cancer risk among smokers. Int J Cancer. 2014 Nov 1;135(9):2135-45. doi: 10.1002/ijc.28846. Epub 2014 Mar 24. PMID: 24622914; PMCID: PMC4293152.
25. World Health Organization. Global Tuberculosis Reports. (2020). Available online at: https://www.who.int/teams/global-tuberculosis-programme/tb-reports (accessed December 19, 2020).
26-Tadolini M, Codecasa L, García-García J, Blanc F, Borisov S, Alffenaar J, et al. Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. (2020) 56:2002328. doi: 10.1183/13993003.02328-2020
27. Promislow DEL. A geroscience perspective on COVID-19 mortality. Js Gerontol Ser A Biol Sci Med Sci. (2020) 75:e30–3. doi: 10.1093/gerona/glaa094 PubMed Abstract | CrossRef Full Text | Google Scholar
28. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3
29-Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. (2020) 55:2001227. doi: 10.1183/13993003.01227-2020
30-World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available online at: https://covid19.who.int/table (accessed December 19, 2020).
31. Callender L, Curran M, Bates S, Mairesse M, Weigandt J, Betts C. The impact of pre-existing comorbidities and therapeutic interventions on COVID-19. Front Immunol. (2020) 11:1991. doi: 10.3389/fimmu.2020.01991
32-Goodman & Gilman’s. The pharmacological basis of therapeutics, 13e | Access medicine. New York City: McGraw-Hill Medical. 2018
33-Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337–352.
34-Garrido-Mesa N, Zarzuelo A, Gálvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169:337–352.
35-Szeto GL, Brice AK, Yang H-C, et al. Minocycline attenuates HIV infection and reactivation by suppressing cellular activation in human CD4+ T cells. J Infect Dis. 2010;201:1132–1140.
36-Seabrook TJ, Jiang L, Maier M, et al. Minocycline affects microglia activation, abeta deposition, and behavior in APP-tg mice. Glia. 2006;53:776–782.
37-Enose-Akahata Y, Matsuura E, Tanaka Y, et al. Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease. Retrovirology. 2012;9:16.
38-Steinberg J, Halter J, Schiller H, et al. Chemically modified tetracycline prevents the development of septic shock and acute respiratory distress syndrome in a clinically applicable porcine model. Shock Augusta Ga. 2005;24:348–356.
39-Sadowsky D, Nieman G, Barclay D, et al. Impact of chemically-modified tetracycline 3 on intertwined physiological, biochemical, and inflammatory networks in porcine sepsis/ARDS. Int J Burns Trauma. 2015;5:22–35
40-Zhou Y-Q, Liu D-Q, Chen S-P, et al. Minocycline as a promising therapeutic strategy for chronic pain. Pharmacol Res. 2018;134:305–310.
41-Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J Affect Disord. 2018;227:219–225.
42-Wu C., Chen X. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020;13
43-Dey, D., Borkotoky, S., & Banerjee, M. (2020). In silico identification of Tretinoin as a SARS-CoV-2 envelope (E) protein ion channel inhibitor. Computers in biology and medicine, 127, 104063. https://doi.org/10.1016/j.compbiomed.2020.104063
44-Morita T, Miyakawa K, Jeremiah SS, Yamaoka Y, Sada M, Kuniyoshi T, Yang J, Kimura H, Ryo A. All-Trans Retinoic Acid Exhibits Antiviral Effect against SARS-CoV-2 by Inhibiting 3CLpro Activity. Viruses. 2021 Aug 23;13(8):1669. doi: 10.3390/v13081669. PMID: 34452533; PMCID: PMC8402917.
45-Riva, L., Yuan, S., Yin, X. et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 586, 113–119 (2020). https://doi.org/10.1038/s41586-020-2577-1
46-Gundogdu M, Dere G. Is systemic isotretinoin use a risk factor for coronavirus disease 2019 (COVID-19)? J Cosmet Dermatol. 2021 Jun;20(6):1568-1570. doi: 10.1111/jocd.14044. Epub 2021 Mar 14. PMID: 33682290; PMCID: PMC8251030.
47-Abdelmaksoud A, Patil A, Dursun R, Temiz SA, Ayhan E, Goldust M, Vestita M. Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective. J Cosmet Dermatol. 2021 Aug;20(8):2394-2395. doi: 10.1111/jocd.14239. Epub 2021 Jun 6. PMID: 34008285; PMCID: PMC8242528.
48-Hamouda Elgarhy L. Could patients taking isotretinoin therapy be immune against SARS-CoV-2? Dermatol Ther. 2020 Jul;33(4):e13573. doi: 10.1111/dth.13573. Epub 2020 May 29. PMID: 32406143; PMCID: PMC7272898.
49-Demir M, Demir F, Aygun H. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease. J Med Virol. 2021 May;93(5):2992-2999. doi: 10.1002/jmv.26832. Epub 2021 Feb 9. PMID: 33512007; PMCID: PMC8013436.
50-Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59(6):881‐886.
51-Khoo AL, Chai L, Koenen H, Joosten I, Netea M, van der Ven A. Translating the role of vitamin D3 in infectious diseases. Crit Rev Microbiol. 2012;38(2):122‐135
52-Karahan S, Katkat F. Impact of Serum 25 (OH) Vitamin D level on mortality in patients with COVID‐19 in Turkey. J Nutr Health Aging. 2020:1‐8
53-Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, et al. Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID‐19: A pilot randomized clinical study. J Steroid Biochem Mol Biol. 2020;203:105751.
54-J. L, B. J, C.E. W, G. R, T.M. C, Antiviral activity of metal chelates of caffeic acid and similar compounds towards herpes simplex, VSV-Ebola pseudotyped and vaccinia viruses, Antivir. Res. 160 (2018) 143–150.
55-S.U. L, C.G. S, C.K. L, Y.S. L, Caffeoylglycolic and caffeoylamino acid derivatives, halfmers of L-chicoric acid, as new HIV-1 integrase inhibitors, Eur. J. Med. Chem. 42 (10) (2007) 1309–1315.
56-L.Z. S, N.L. C, S.C. M, The American coneflower: a prophylactic role involving nonspecific immunity, J. Alternative Compl. Med. 5 (5) (1999) 437–446.
57-A. Wacker, W. Hilbig, Virushemmung mit Echinacea purpurea, Planta Med. 33 (1) (1978) 89–102.